Oxford BioMedica PLC (OXB)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

299.00p

Buy

302.00p

arrow-up6.00p (+2.03%)

Oxford BioMedica PLC is a biopharmaceutical company based in the United Kingdom. It develops gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.
Prices updated at 16 May 2025, 16:35 BST
| Prices minimum 15 mins delay
|
Prices in GBX
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Roch F. Doliveux
CEO
Dr. Frank Mathias
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
861
Head office
Windrush Court
Oxford
United Kingdom
OX4 6LT
mobile
+44 1865783000
letter
enquiries@oxb.com

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Stuart Henderson
Non-Executive Director, Vice Chairman
---0.09m-
Professor Dame Kay Davies
Non-Executive Director, Senior Independent Director
-----
Dr. Roch F. Doliveux
Non-Executive Director, Chairman
---0.23m-
Dr. Heather Elizabeth Preston, M.D.
Non-Executive Director
---0.08m-
Ms. Namrata P Patel
Non-Executive Director
---0.07m-
Ms. Lucinda Crabtree
Executive Director, Chief Financial Officer
-----
Dr. Frank Mathias
Executive Director, Chief Executive Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
M&G Investment Management Limited5,184,9483.54693-239685-30 Apr 20254.89
M&G Recovery Fund4,583,8142.04493-239685-4.96911130 Apr 20254.32
Liontrust Fund Partners LLP2,151,8841.17918-2092738-30 Apr 20252.03
Zurich Ltd.1,866,4462.79801--30 Apr 20251.76
BlackRock Smaller Companies1,817,2951.1029522997614.48832930 Apr 20251.71

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
No data
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.